Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe parkinsonian's patients

被引:0
|
作者
Vaamonde, J [1 ]
Ibàñez, R [1 ]
Gudin, M [1 ]
Hernández, A [1 ]
机构
[1] Complejo Hosp Ciudad Real, Serv Neurol, Ciudad Real 13002, Spain
来源
NEUROLOGIA | 2003年 / 18卷 / 03期
关键词
Parkinson's disease; severity; motor complications;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Daily fluctuations of motor performance and dyskinesias in patients with Parkinson's disease (PD) treated with levodopa represent a difficult challenge to our understanding. We report 10 patients diagnosed of severe PD (Hoehn and Yahr: III-IV/V) treated with levodopa (range of dose: 750-900 mg/day) in single drug therapy since their diagnosis (mean time of levodopatherapy: 4.8 +/- 2.4 months, range: 3-6 months). All patients developed motor complications within weeks to months after initiating L-dopatherapy. Two patients received an intravenous apomorphine infusion (mean dose: 8.5 mg/day) during a mean time of 7.5 hours, but motor complications persisted during the infusion in spite of continuous dopaminergic stimulus. The degree of nigrostriatal damage (disease severity) seems to be a very important risk factor for the development of treatment-related motor complications.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [31] 4-Chlorokynurenine inhibits L-Dopa-induced dyskinesias in non-human parkinsonian primates
    Di Paolo, T.
    Bourque, M.
    Snodgrass, R.
    MOVEMENT DISORDERS, 2020, 35 : S123 - S123
  • [32] Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease.
    Maurel, F
    Lilliu, H
    Le Pen, C
    REVUE NEUROLOGIQUE, 2001, 157 (05) : 507 - 514
  • [33] Beneficial effects of amantadine on L-Dopa-induced dyskinesias in Parkinson's disease
    Luginger, E
    Wenning, GK
    Bösch, S
    Poewe, W
    MOVEMENT DISORDERS, 2000, 15 (05) : 873 - 878
  • [34] Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease
    Mazzucchi, S.
    Frosini, D.
    Ripoli, A.
    Nicoletti, V.
    Linsalata, G.
    Bonuccelli, U.
    Ceravolo, R.
    ACTA NEUROLOGICA SCANDINAVICA, 2015, 131 (03): : 191 - 195
  • [35] Calcium homeostasis is dysregulated in parkinsonian patients with L-Dopa induced dyskinesias
    Blandini, F.
    Bazzini, E.
    Marino, F.
    Saporiti, F.
    Armentero, M. -T.
    Pacchetti, C.
    Zangaglia, R.
    Martignoni, E.
    Lecchini, S.
    Nappi, G.
    Cosentino, M.
    MOVEMENT DISORDERS, 2008, 23 (01) : S88 - S88
  • [36] Calcium homeostasis is dysregulated in parkinsonian patients with L-dopa induced dyskinesias
    Blandini, F.
    Bazzini, E.
    Marino, F.
    Saporiti, F.
    Armentero, M. T.
    Pacchetti, C.
    Zangaglia, R.
    Martignoni, E.
    Lecchini, S.
    Nappi, G.
    Cosentino, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 102 - 103
  • [37] The effect of unilateral pallidotomy on motor disability, and L-dopa-induced dyskinesia in parkinsonian marmosets
    Iravani, MM
    Costa, S
    Jackson, MJ
    Al-Bargouthy, G
    Jenner, P
    MOVEMENT DISORDERS, 2002, 17 : S93 - S93
  • [38] Role of Serotonin Neurons in the Development of L-DOPA-Induced Dyskinesias
    Carta, M.
    MOVEMENT DISORDERS, 2010, 25 : S583 - S583
  • [39] The α7 Nicotinic Receptor Agonist ABT-107 Decreases L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys
    Zhang, Danhui
    McGregor, Matthew
    Decker, Michael W.
    Quik, Maryka
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 351 (01): : 25 - 32
  • [40] Altered inhibitory interaction among inferior frontal and motor cortex in l-dopa-induced dyskinesias
    Ponzo, Viviana
    Picazio, Silvia
    Benussi, Alberto
    Di Lorenzo, Francesco
    Brusa, Livia
    Caltagirone, Carlo
    Koch, Giacomo
    MOVEMENT DISORDERS, 2016, 31 (05) : 755 - 759